Clinical Trial

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV

Study acronym: 9vHPV-BCG
Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1. Treat Infection of Multiple HPV Virus Strains via Trained Immunity. 2. Activate human HPV Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the HPV virus protein antigens into small peptide fragments, and then clear HPV virus in vivo.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-05; most recent amendment 2026-05-18.
Trial Details
NCT Number NCT06959563
Lead Sponsor Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Collaborators: UnitedHealthcare
Conditions HPV Infection
Enrollment 20 participants
Start Date 2025-04-28
Primary Completion 2026-10-18 (estimated)
Study Completion 2026-10-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-20